All news

Mass production of Epivaccorona vaccine to be launched in February

To date, 3,591,066 coronavirus cases have been confirmed in Russia, with 2,978,764 patients having recovered from the disease

MOSCOW, January 18. /TASS/. Mass production of another Russian anti-coronavirus vaccine, Epivaccorona, will be launched in February 2021, Russian Deputy Prime Minister Tatiana Golikova said on Monday.

"We will begin mass production of the Epivaccorona vaccine developed by the Vector Center in February 2021," she said.

On July, 24, 2020, the Vector State Research Center of Virology and Biotechnology received a Russian health ministry permit for clinical trials of its anti-coronavirus vaccine on volunteers. The first volunteer was inoculated on July 27. The vaccine’s clinical trials were completed on September 30. Russian President Vladimir Putin said on October 14 that the Vector-developed vaccine had received registration. On November 16, the health ministry issued a permit for post-registration trials of the vaccine on volunteers older than 60 and a permit for tests on 3,000 volunteers aged from 18 to 60 was issued on November 18.

To date, 3,591,066 coronavirus cases have been confirmed in Russia, with 2,978,764 patients having recovered from the disease. Russia’s latest data indicates 66,037 fatalities nationwide. Earlier, the Russian government set up an Internet hotline to keep the public updated on the coronavirus situation.